The Governance Gap in Clinical Trial Operations AI

Two Different AI Problems, One Regulatory Vocabulary

The FDA has now authorized roughly 1,500 AI-enabled medical devices, and the evidence base for most of them is still catching up to the authorization itself, according to Clinical Trial Vanguard. That is a real problem, and it is the one getting nearly all the regulatory attention right now, including the FDA’s reported interest in a more doctor-like, judgment-based review model for AI devices, per Axios.

But device authorization is not the same governance problem as what is happening inside trial operations. Enrollment matching, protocol feasibility scoring, site monitoring, and now full agentic platforms for drug development are being deployed by sponsors and CROs under no comparable authorization pathway at all. Bioxconomy reports that regulatory uncertainty is actively stalling AI adoption in the trials sector, with sponsors waiting on FDA guidance that does not yet exist for this layer of the workflow. TCS’s newly launched agentic AI platform for drug development is a useful marker of how fast vendors are moving into that vacuum, per TCS’s own announcement, and it should be read as a vendor’s pace claim, not a compliance claim.

The Gap Is Structural, Not Temporary

Europe illustrates why this gap will not close quickly. The EU AI Act has substantive teeth for high-risk systems, but its application to medical AI has been effectively deferred, leaving sponsors operating on MDR/IVDR logic that was never built for adaptive, learning software, as Fransiscus Nanga Roka argues. Device-specific authorization routes are emerging, as Medical Buyer notes, but they are scoped to devices, not to the operational software stitching a trial together. The IMDRF Category III/IV high-risk SaMD market is forecast to grow substantially through 2036, per Fact.MR, which tells you where regulatory infrastructure is being built. It is not being built for trial operations tooling.

The counterargument deserves airing. Sponsors already operate under GCP, 21 CFR Part 11, and increasingly ISO 42001 management-system discipline, and a rigorous quality organization could argue these frameworks already cover AI vendors by extension, treating any AI tool touching trial data as subject to the same validation and audit-trail requirements as any other computerized system. MDDI’s analysis of the medtech innovation paradox supports this view: rigor and agility are already in tension inside existing device frameworks, and stretching them further is plausible.

The trouble is that even inside the regulated device pathway, transparency is inconsistent. Frontiers’ analysis of FDA public summaries found real fairness gaps in what authorized AI devices disclose about their own performance across populations. If that is the documentation quality inside the system with the most scrutiny, extending informal quality-system logic to unauthorized trial-operations AI, with no device-level review at all, is a weaker bet than it sounds.

What Sponsors Should Actually Require

Vendor pace claims, including sponsor press releases citing “regulatory readiness” ahead of trial milestones such as IGC Pharma’s Phase 2 update, are not a substitute for contractual governance terms. Sponsors and CROs should require ISO 42001 certification or equivalent evidence from any AI vendor touching trial operations, regardless of FDA device status, because no framework currently in force will do that verification for them.

---

Board record

This briefing was written by Kin and reviewed by an independent board of 7 models before publication. Ruling: CLEARED.

Seat	Reviewer	Finding
Chair · Editorial Judgment	Claude	cleared. The argument is structurally sound and honestly engages its strongest counterargument (existing GCP/Part 11 frameworks), but the final recommendation (require ISO 42001) arrives somewhat abruptly with
Source & Claim Verification	Qwen · local	cleared. All factual claims are traced to citations, but some sources could be more robust or specific for full verification.
Regulatory & Framework Fidelity	Mistral	cleared. The briefing accurately reflects ISO 42001, EU AI Act, and FDA/MDR/IVDR frameworks but overstates the sufficiency of ISO 42001 certification as a standalone solution without addressing its implementat
Technical Accuracy	Llama	cleared. The article accurately describes the current regulatory landscape for AI in clinical trial operations, but could be strengthened with more technical details on AI implementations.
Bias, Balance & Hype Control	Gemini	cleared. The briefing effectively identifies and addresses potential counterarguments, clearly distinguishing between vendor hype and verifiable claims.
Novelty & Non-Duplication	Grok	held. The device-vs-trial-ops governance gap is a modest synthesis, but the brief largely restates existing wire points (Bioxconomy uncertainty stall, FDA device-authorization volume, EU AI Act deferral) wi
Validation	DeepSeek	cleared. The central claim that AI tools for clinical trial operations operate without a formal authorization pathway comparable to medical devices is validated by multiple sources citing regulatory uncertaint

Sources cited: 15. Validation challenges: 0. Review cost: about $0.04. Learn how these briefings are written and verified.